Interaction Checker

Nintédanib : interactions médicamenteuses

Nintédanib (Ofev) présente 150 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 0 de niveau majeur, 149 de niveau modéré, 0 de niveau mineur et 1 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions modérées (149)

  • Acide méfénamiqueAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • AmiodaroneantiarythmiqueModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • ApixabananticoagulantModérée

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (notice Nintédanib, Interactions médicamenteuses)

  • Aprépitantinhibiteur du CYP3A4Modérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • ArgatrobananticoagulantModérée

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (notice Nintédanib, Interactions médicamenteuses)

  • Armodafinilstimulant du SNCModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • AspirineAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Aspirine et dipyridamoleantiagrégant plaquettaireModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • AtazanavirantirétroviralModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • Azélastine et fluticasoneantihistaminiqueModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • BéclométasonecorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • BétaméthasonecorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • BivalirudineanticoagulantModérée

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (notice Nintédanib, Interactions médicamenteuses)

  • Bosentaninducteur du CYP3A4Modérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • BudésonidecorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Budésonide et formotérolcorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Butalbital, aspirine et caféinebarbituriqueModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Butalbital, aspirine, caféine et codéinebarbituriqueModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • CarbamazépineanticonvulsivantModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • CélécoxibAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • CénobamateanticonvulsivantModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • CiclésonidecorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • CiclosporineimmunosuppresseurModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • Cimétidineantihistaminique H2Modérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • Clarithromycineantibiotique macrolideModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • ClobazambenzodiazépineModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • ClobétasolcorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • DabigatrananticoagulantModérée

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (notice Nintédanib, Interactions médicamenteuses)

  • DarunavirantirétroviralModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • Darunavir et cobicistatantirétroviralModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • Déférasiroxsupplément de ferModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • DéflazacortcorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Désogestrel et éthinylestradiolcontraceptif oralModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • DésonidecorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • DexaméthasonecorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Diacétate d'étynodiol et éthinylestradiolcontraceptif oralModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • DiclofénacAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Diclofénac et misoprostolAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • DiflunisalAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Diltiazeminhibiteur calciqueModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • DronédaroneantiarythmiqueModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • Drospirénone et éthinylestradiolcontraceptif oralModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • ÉdoxabananticoagulantModérée

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (notice Nintédanib, Interactions médicamenteuses)

  • ÉfavirenzantirétroviralModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • Éfavirenz, lamivudine et ténofovirantirétroviralModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • Elvitégravir, cobicistat, emtricitabine et ténofovirantirétroviralModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • ÉnoxaparineanticoagulantModérée

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (notice Nintédanib, Interactions médicamenteuses)

  • Érythromycineantibiotique macrolideModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • EslicarbazépineanticonvulsivantModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • EstradiolestrogèneModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • Estradiol et diénogestcontraceptif oralModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • Estradiol et noréthistéroneestrogèneModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • Estrogènes conjuguésestrogèneModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • Estrogènes conjugués et bazédoxifèneestrogèneModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • Estrogènes estérifiés et méthyltestostéroneestrogèneModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • ÉtodolacAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Étonogestrel et éthinylestradiolestrogèneModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • ÉtravirineantirétroviralModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • ÉvérolimusimmunosuppresseurModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • FénoprofèneAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Fluconazoleantifongique azoléModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • FludrocortisonecorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • FlunisolidecorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • FluocinonidecorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • FlurbiprofèneAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • FluticasonecorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Fluticasone et salmétérolcorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • FondaparinuxanticoagulantModérée

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (notice Nintédanib, Interactions médicamenteuses)

  • FosamprénavirantirétroviralModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • Fosaprépitantinhibiteur du CYP3A4Modérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • FosphénytoïneanticonvulsivantModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • FulvestrantestrogèneModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • GriséofulvineantifongiqueModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • HalobétasolcorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • HéparineanticoagulantModérée

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (notice Nintédanib, Interactions médicamenteuses)

  • Hydrocodone et ibuprofèneopioïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • HydrocortisonecorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • IbuprofèneAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Ibuprofène et famotidineAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Imatinibinhibiteur du CYP3A4Modérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • IndométacineAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • IsoniazideantibiotiqueModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • Itraconazoleantifongique azoléModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • Ivacaftorinhibiteur du CYP3A4Modérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • Kétoconazoleantifongique azoléModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • KétoprofèneAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • KétorolacAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • LénacapavirantirétroviralModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • LévonorgestrelprogestatifModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • Lévonorgestrel et éthinylestradiolcontraceptif oralModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • Lopéramidemédicament allongeant l'intervalle QTModérée

    Treat diarrhea at first signs with adequate hydration and antidiarrheal medication (e.g., loperamide), and consider dose reduction or treatment interruption if diarrhea continues [see Dosage and Administration (2.4) ]. (notice Nintédanib, Mises en garde et précautions)

  • Lopinavir et ritonavirantirétroviralModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • Lorlatinibinducteur du CYP3A4Modérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • MédroxyprogestéroneprogestatifModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • MégestrolprogestatifModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • MéloxicamAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • MéthylprednisolonecorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Mifépristoneinhibiteur du CYP3A4Modérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • Mirabégronagoniste bêta-adrénergiqueModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • Mitapivatinducteur du CYP3A4Modérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • Mitotaneinducteur du CYP3A4Modérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • Modafinilstimulant du SNCModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • MométasonecorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • NabumétoneAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Nafcillineantibiotique de la famille des pénicillinesModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • NaproxèneAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Naproxène et ésoméprazoleAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • NéfazodoneantidépresseurModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • NévirapineantirétroviralModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • Nirmatrelvir et ritonavirantiviralModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • Norelgestromine et éthinylestradiolestrogèneModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • NoréthistéroneprogestatifModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • Noréthistérone et éthinylestradiolcontraceptif oralModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • Norgestimate et éthinylestradiolcontraceptif oralModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • Norgestrel et éthinylestradiolcontraceptif oralModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • Olopatadine et mométasoneantihistaminiqueModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Orphénadrine, aspirine et caféinemyorelaxantModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • OxaprozineAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • OxcarbazépineanticonvulsivantModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • Palbociclibinhibiteur du CYP3A4Modérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • Paracétamol et ibuprofèneAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • PérampanelanticonvulsivantModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • PhénobarbitalbarbituriqueModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • Phentermine et topiramatestimulant du SNCModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • PhénytoïneanticonvulsivantModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • PiroxicamAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Posaconazoleantifongique azoléModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • PrednisolonecorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • PrednisonecorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • PrimidoneanticonvulsivantModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • ProgestéroneprogestatifModérée

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (notice Nintédanib, Mises en garde et précautions)

  • Ranolazinemédicament allongeant l'intervalle QTModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • RifabutineantibiotiqueModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • RifampicineantibiotiqueModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • RifapentineantibiotiqueModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • RitonavirantirétroviralModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • RivaroxabananticoagulantModérée

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (notice Nintédanib, Interactions médicamenteuses)

  • SalsalateAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • SulindacAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Sumatriptan et naproxènetriptanModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Suvorexantsédatif-hypnotiqueModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • Suzétrigineinducteur du CYP3A4Modérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • Ticagrélorantiagrégant plaquettaireModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • TolmétineAINSModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • TopiramateanticonvulsivantModérée

    Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (notice Nintédanib, Interactions médicamenteuses)

  • TriamcinolonecorticoïdeModérée

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

  • Vérapamilinhibiteur calciqueModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • Voriconazoleantifongique azoléModérée

    Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (notice Nintédanib, Interactions médicamenteuses)

  • WarfarineanticoagulantModérée

    Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (notice Nintédanib, Interactions médicamenteuses)

Aucune interaction significative signalée (1)

  • PirfénidoneAucune interaction

    Pirfenidone In a multiple-dose study conducted to assess the pharmacokinetic effects of concomitant treatment with nintedanib and pirfenidone, the coadministration of nintedanib with pirfenidone did not alter the exposure of either agent [see Clinical Pharmacology (12.3) ] . (notice Nintédanib, Interactions médicamenteuses)

Vérifiez Nintédanib avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.